Xintela AB (FRA:1XT) Other Stockholders Equity: €0.03 Mil (As of Mar. 2026)


FRA:1XT Xintela AB FRA:1XT
8 GF Score
Price €0.01
! 2 Warning Signs
View Full Analysis

What is Xintela AB Other Stockholders Equity?

Xintela AB FRA:1XT 8 Other Stockholders Equity is €0.03 Mil as of Mar. 2026. GuruFocus rates FRA:1XT with a GF Score™ of 8/100. The stock has 2 warning signs investors should review.

Xintela AB's Other Stockholders Equity for the quarter that ended in Mar. 2026 was €0.03 Mil.

Xintela AB's quarterly Other Stockholders Equity increased from Sep. 2025 (€0.03 Mil) to Dec. 2025 (€0.07 Mil) but then declined from Dec. 2025 (€0.07 Mil) to Mar. 2026 (€0.03 Mil).

Xintela AB's annual Other Stockholders Equity declined from Dec. 2023 (€0.12 Mil) to Dec. 2024 (€0.05 Mil) but then increased from Dec. 2024 (€0.05 Mil) to Dec. 2025 (€0.07 Mil).

Xintela AB Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Xintela AB's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xintela AB Other Stockholders Equity Chart

Xintela AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.00 0.04 0.12 0.05 0.07

Xintela AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.02 0.03 0.07 0.03
FRA:1XT
8GF Score
Xintela AB FRA:1XT
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xintela AB Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €0.03 Mil mean?
Xintela AB (FRA:1XT) has a Other Stockholders Equity of €0.03 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Xintela AB and its competitors.
Is Xintela AB's Other Stockholders Equity too high?
Xintela AB's current Other Stockholders Equity is €0.03 Mil. Overall, Xintela AB has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Xintela AB's Other Stockholders Equity compare to VRTX and REGN?
Xintela AB's Other Stockholders Equity of €0.03 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Biotechnology company?
A good Other Stockholders Equity depends on the Biotechnology industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Xintela AB and its competitors. Xintela AB's current Other Stockholders Equity is €0.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xintela AB stock overvalued right now?
Xintela AB (FRA:1XT) has a current Other Stockholders Equity of €0.03 Mil. The current Other Stockholders Equity is €0.03 Mil. Xintela AB's overall GF Score™ is 8/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Xintela AB (FRA:1XT), the current Other Stockholders Equity is €0.03 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Xintela AB Business Description

Other Exchanges XINT:Sweden
Address Medicon Village, Lund, SWE, 223 81
Xintela AB is a clinical-stage biopharmaceutical company that develops cutting-edge medical products in stem cell therapy and targeted cancer therapy. Its wholly owned subsidiary, Targinta AB, develops First-in-Class therapeutic antibodies targeting integrin ?10?1. TARG9, an antibody-drug conjugate (ADC), and TARG10, a function-blocking antibody, are in preclinical development for the treatment of aggressive, difficult-to-treat cancers, including triple-negative breast cancer and brain tumor glioblastoma. Xintela has two clinical studies ongoing with the stem cell product XSTEM and EQSTEM.
8GF Score

Get the complete analysis for FRA:1XT

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.01
Price